Paper Details
- Home
- Paper Details
Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Author: CroftSimon L, HarrisAndy, MurdanSudaxshina, Van BocxlaerKatrien, WijnantGert-Jan, YardleyVanessa
Original Abstract of the Article :
AmBisome (LAmB), a liposomal formulation of amphotericin B (AmB), is a second-line treatment for the parasitic skin disease cutaneous leishmaniasis (CL). Little is known about its tissue distribution and pharmacodynamics to inform clinical use in CL. Here, we compared the skin pharmacokinetics of LA...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826151/
データ提供:米国国立医学図書館(NLM)
AmBisome for Cutaneous Leishmaniasis: A Pharmacokinetic and Efficacy Study
Cutaneous leishmaniasis (CL), a parasitic skin disease caused by Leishmania parasites, is a significant health concern in many parts of the world. This study examines the pharmacokinetics and efficacy of AmBisome, a liposomal formulation of amphotericin B, in treating murine models of CL. The researchers compared AmBisome with the deoxycholate form of amphotericin B (DAmB), finding that AmBisome achieved higher drug levels at the target site (the lesion) and demonstrated improved efficacy in reducing parasite load and lesion size. The study highlights the importance of considering drug delivery systems and their impact on drug distribution and therapeutic outcomes in treating CL.
Improving Treatment for Cutaneous Leishmaniasis: A Focus on Drug Delivery Systems
The study underscores the importance of drug delivery systems in optimizing treatment for CL. The researchers demonstrated that AmBisome, a liposomal formulation of amphotericin B, achieved higher drug levels at the lesion site and showed improved efficacy in reducing parasite load and lesion size compared to DAmB. This finding emphasizes the need for further research into drug delivery systems to improve therapeutic outcomes in treating CL.
Navigating the Desert of Parasitic Infections: Finding Effective Treatments
Imagine traversing a vast desert, where the landscape is riddled with hidden dangers. This analogy reflects the challenges associated with treating parasitic infections like CL. This study offers valuable insights into the potential of drug delivery systems like AmBisome to improve treatment outcomes, guiding us towards more effective therapies for managing these infections.
Dr.Camel's Conclusion
This study highlights the importance of drug delivery systems in optimizing treatment for cutaneous leishmaniasis. The researchers demonstrated that AmBisome, a liposomal formulation of amphotericin B, achieved higher drug levels at the lesion site and showed improved efficacy in reducing parasite load and lesion size compared to DAmB. The findings underscore the need for continued research into drug delivery systems to enhance therapeutic outcomes in treating CL and other parasitic infections.
Date :
- Date Completed 2019-05-14
- Date Revised 2022-04-08
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.